^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
Title:

TP-0903 is active in models of drug-resistant acute myeloid leukemia

Published date:
12/03/2020
Excerpt:
We also showed that TP-0903 had ex vivo activity in primary AML cells with recurrent mutations including MLL-PTD, ASXL1, SRSF2, and WT1, which are associated with poor prognosis or promote clinical resistance to AML-directed therapies.
DOI:
10.1172/jci.insight.140169